Kochhar Sonali, Knoppers Bartha, Gamble Carrol, Chant Alan, Koplan Jeffrey, Humphreys Georgina S
Global Healthcare Consulting, New Delhi, India.
Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands.
BMJ Open. 2019 Aug 21;9(8):e032334. doi: 10.1136/bmjopen-2019-032334.
Anonymised patient-level data from clinical research are increasingly recognised as a fundamental and valuable resource. It has value beyond the original research project and can help drive scientific research and innovations and improve patient care. To support responsible data sharing, we need to develop systems that work for all stakeholders. The members of the Independent Review Panel (IRP) for the data sharing platform Clinical Study Data Request (CSDR) describe here some summary metrics from the platform and challenge the research community on why the promised demand for data has not been observed.
From 2014 to the end of January 2019, there were a total of 473 research proposals (RPs) submitted to CSDR. Of these, 364 met initial administrative and data availability checks, and the IRP approved 291. Of the 90 research teams that had completed their analyses by January 2018, 41 reported at least one resulting publication to CSDR. Less than half of the studies ever listed on CSDR have been requested.
While acknowledging there are areas for improvement in speed of access and promotion of the platform, the total number of applications for access and the resulting publications have been low and challenge the sustainability of this model. What are the barriers for data contributors and secondary analysis researchers? If this model does not work for all, what needs to be changed? One thing is clear: that data access can realise new and unforeseen contributions to knowledge and improve patient health, but this will not be achieved unless we build sustainable models together that work for all.
临床研究中经过匿名处理的患者层面数据日益被视为一项基础且宝贵的资源。它的价值超越了原始研究项目,有助于推动科学研究与创新,并改善患者护理。为支持负责任的数据共享,我们需要开发适用于所有利益相关者的系统。数据共享平台临床研究数据请求(CSDR)的独立审查小组(IRP)成员在此介绍该平台的一些汇总指标,并就为何未观察到预期的数据需求向研究界提出质疑。
从2014年到2019年1月底,共有473项研究提案(RP)提交至CSDR。其中,364项通过了初步行政和数据可用性检查,IRP批准了291项。在截至2018年1月已完成分析的90个研究团队中,有41个向CSDR报告了至少一篇研究成果发表情况。在CSDR上列出的研究中,被请求的研究不到一半。
虽然承认在平台访问速度和推广方面仍有改进空间,但访问申请总数和由此产生的出版物数量一直较低,这对该模式的可持续性提出了挑战。数据提供者和二次分析研究人员面临的障碍是什么?如果这种模式不适用于所有人,需要做出哪些改变?有一点是明确的:数据访问能够为知识带来新的、意想不到的贡献,并改善患者健康,但除非我们共同构建适用于所有人的可持续模式,否则这一目标无法实现。